Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2026 am IST			5-day change	1st Jan Change
129.58 ^USD	-1.88%		-1.33%	+5.57%

15/05	Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health	RE
15/05	Wall Street Wanted More

Health Care Up as Trump Administration Boosts Medicare Rate Proposal -- Health Care Roundup

Published on 04/08/2026 at 03:02 am IST

Dow Jones

GILEAD SCIENCES, INC.

-1.88%

UNITEDHEALTH GROUP INC.

-1.31%

NEUROCRINE BIOSCIENCES, INC.

-0.40%

SOLENO THERAPEUTICS, INC.

+0.04%

Health-care companies rose after a Medicare rates proposal was much higher than previous estimates.

Shares of Humana and UnitedHealth Group, two of the health insurers hardest hit when a preliminary proposal for Medicare payments from the government was more or less flat for 2027, shot up after the latest estimate. Under the new proposal, the Trump administration would raise payments to Medicare insurers by 2.48% next year.

Shares of some biotech companies rose after closely held German biotech firm Tubulis agreed to a buyout from biopharmaceutical giant Gilead Sciences for up to $5 billion, as Gilead seeks to build up its oncology pipeline. It was the latest in a series of deals in the niche, following the recently unveiled merger plan between Neurocrine Biosciences and Soleno Therapeutics.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-07-26 1731ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
GILEAD SCIENCES, INC.	129.58USD	-1.88%	-1.33%	16TCr
UNITEDHEALTH GROUP INC.	393.85USD	-1.31%	+3.65%	36TCr
NEUROCRINE BIOSCIENCES, INC.	158.42USD	-0.40%	+4.05%	1.59TCr
SOLENO THERAPEUTICS, INC.	53.01USD	+0.04%	+0.11%	276.29Cr

Latest news about Gilead Sciences, Inc.

15/05	Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health	RE
15/05	Wall Street Wanted More
15/05	Gilead Sciences Prices $3 Billion Debt Offering	MT
15/05	Gilead files for four part senior notes offering of up to $3 billion - SEC filing	RE
14/05	Gilead - files for offering of four-part senior notes size not disclosed - SEC filing	RE
13/05	US FDA approves BeOne's drug for a type of blood cancer	RE
13/05	Gilead Sciences, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02:20 PM
11/05	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
11/05	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
08/05	Gilead Sciences Faces Long-Term Questions on Yeztugo Growth, RBC Capital Markets Says	MT
08/05	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
08/05	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
08/05	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT
08/05	A lot of noise, little impact?
08/05	Gilead Sciences, Inc., Q1 2026 Earnings Call, May 07, 2026

Chart Gilead Sciences, Inc.

Duration

Period

GILD: Dynamic Chart

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).

Employees

17,000

Sector

Pharmaceuticals

Calendar

15/06 - Ex-dividend date - 0.82 USD

More about the company